In this section of the site, the tabs opened here will provide general background information about several important clinical research topics. One of the most common concerns raised by potential research participants or volunteers is: “I don’t want to be a guinea pig.” In the distant past, there were human studies conducted that did not adequately safeguard research volunteers, such as the appropriately notorious Tuskeegee syphilis study (for more, go to Racism and Research) in which African American men with syphilis were unknowingly denied treatment as part of a long term observation of the effects of untreated syphilis. These abuses were widely publicized, and as a result, human clinical research is now tightly regulated and monitored. Clinical research is still research, in that nobody can state the outcome of a study until it has been completed, and as a result, research studies will always have some element of known and unknown risk. However, potential volunteers can only enter studies after informed consent – and participants are free to withdraw from a study at any time for any reason without any type of retaliation. Research protocols must be designed to minimize risk and maximize potential benefit, and must pass the scrutiny of independent Institutional Review Boards (IRB) comprised of both professional and lay people having no connection to those sponsoring the research study under review. We hope that the topics covered here will provide both reassurance and valuable information for those of you who may wish to volunteer for a clinical research study.
2 months ago
Learn about an Idiopathic Pulmonary Fibrosis (IPF) Research Study Now Enrolling Locally.
Clinical trials or studies are important for medical advances. Current treatments for diseases are only available because of research study volunteers.
Although much IPF research has been done, current treatment options remain limited. However, the GALACTIC-1 study is researching treatment for these patients and may offer new hope in IPF. Thank you for considering participation in this trial.
GALACTIC-1 is studying an investigational drug for patients who have IPF. The purpose of this study is to find out if the investigational drug works and to determine its safety.
You may qualify for this study if:
• You are between 40 and 90 years of age
• You have been diagnosed with Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis (IPF) patients and their loved ones are invited to learn about the GALACTIC-1 study by visiting Galactic1IPFStudy.com. ... See MoreSee Less
4 months ago
WE ARE LOOKING FOR WOMEN OF A...ahem...*CERTAIN AGE*...WHO HAVE HOTFLASHES! CALL 334-504-7020! ... See MoreSee Less
Currently enrolling people in studies for COPD, asthma, endometriosis, uterine fibroids, heart failure, and more! ... See MoreSee Less
2 years ago
Here's the one who started it all: our principle Principle Investigator, Dr. Rob Garver, founder/owner of both SEC Lung and SEC Clinical Research. Dr. Garver has been practicing medicine for over 30 years, including 20 years as an attending physician/Professor of Medicine at UAB Hospital in Birmingham, AL. He attended medical school at The Johns Hopkins School of Medicine, where he also completed his Internal Medicine training. He completed his Pulmonary Fellowship at the National Heart, Lung, and Blood Institute and his Critical-Care Medicine Fellowship at UAB. Dr. Garver has been working as a PI for over five years and has participated in numerous research protocols, including COPD, COPD exacerbation, asthma, asthma exacerbation, endometriosis, uterine fibroids, congestive heart failure, and chronic kidney disease ... See MoreSee Less